Proactive Investors - Run By Investors For Investors

IXICO secures medical imaging contract for Huntington’s disease Phase III clinical trial

The contract will involve the collection of magnetic resonance imaging (MRI) data from specialist imaging centres to support the development of a drug
Nerves in the brain
The company will use AI to provide insight into the structure of brain cells and nerves

IXICO PLC (LON:IXI) shares soared higher on Tuesday on news the firm has inked a contract with a top 10 pharmaceutical company to provide imagining services for a Pivotal Phase III clinical trial into Huntington’s disease.

The contract, which is to be delivered over four years and carries a value of £9.1mln, extends the company's relationship with an existing client and is its fourth new contract relating to Huntington’s disease in the current financial year.

READ: IXICO expands contract with biopharmaceutical company

Ixico also expanded its contract with another biopharmaceutical company last month to €1.3mln, which focused on the treatment of another neurodegenerative disease, Alzheimer’s.

Giulio Cerroni, chief executive of IXICO, said the new award, combined with the company’s other contract wins and extensions this year, provided a “strong foundation” for future growth, adding that Huntington’s was an area of “significant unmet medical need” as there are currently no effective marketed treatments.

In mid-morning trading, IXICO was the second biggest London market gainer board, with its shares up 29.1% at 35.50p.

 -- Adds share price --

View full IXI profile View Profile

IXICO PLC Timeline

December 11 2018

Related Articles

June 27 2018
Lancor Scientific is aiming to carry out an initial coin offering by issuing Medici, a new currency based on Ethereum to help Tumour Trace to fund further development
Cancer cells
February 06 2019
In October 2018, Maxcyte saw the first patient dosed in an initial phase I trial using its lead MCY-M11 therapy, tracking a total of 15 women with relapsed or hard-to-treat forms of cancer
test tubes
Summit Therapeutics' potential breakthrough targets C.difficile

© Proactive Investors 2019

Proactive Investors Limited, trading as “Proactiveinvestors United Kingdom”, is Authorised and regulated by the Financial Conduct Authority.
Registered in England with Company Registration number 05639690. Group VAT registration number 872070825 FCA Registration number 559082. You can contact us here.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use